For 20 years, dual antiplatelet therapy (DAPT), consisting of the combination of aspirin and a
platelet P2Y12 receptor inhibitor, has been the gold standard of antithrombotic …

Background: The benefit of dual antiplatelet therapy (DAPT) for reducing ischemic events is
greatest in the early period of acute coronary syndrome, and recent randomized controlled …

Dual antiplatelet therapy has long been the standard of care in preventing coronary and
cerebrovascular thrombotic events in patients with chronic coronary syndrome and acute …

Introduction Dual antiplatelet therapy (DAPT) following percutaneous coronary intervention
(PCI) reduces major adverse cardiovascular events (MACE) and stent thrombosis. However …

Background: The benefit of clopidogrel monotherapy after 1-month dual antiplatelet therapy
(DAPT) compared with 12-month DAPT with aspirin and clopidogrel was demonstrated in …

Background High platelet reactivity (HPR) is associated with subsequent thrombotic events
in patients undergoing percutaneous coronary intervention (PCI). Recently, the ABCD …

Background To assess the performance of the Academic Research Consortium High
Bleeding Risk (ARC-HBR) criteria in stratifying the risk of bleeding and ischaemic events …

Background: The PARIS and CREDO-Kyoto risk scores were developed to identify patients
at risks of thrombotic and bleeding events individually after percutaneous coronary …

Background High bleeding risk (HBR) and complex percutaneous coronary intervention
(PCI) are major determinants for dual antiplatelet therapy (DAPT) duration. Objectives The …

Background Coronary angiography (CAG) is the standard imaging modality for guiding
percutaneous coronary interventions (PCI). Intracoronary imaging techniques such as …